214 related articles for article (PubMed ID: 26907658)
1. Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.
Hefti E; Blanco JG
J Pediatr Hematol Oncol; 2016 May; 38(4):283-7. PubMed ID: 26907658
[TBL] [Abstract][Full Text] [Related]
2. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
[TBL] [Abstract][Full Text] [Related]
3. Vincristine pharmacokinetics in children with Down syndrome.
Lönnerholm G; Frost BM; Söderhäll S; de Graaf SS
Pediatr Blood Cancer; 2009 Jan; 52(1):123-5. PubMed ID: 18615507
[TBL] [Abstract][Full Text] [Related]
4. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.
Valle M; Plon SE; Rabin KR
Leuk Res; 2009 Feb; 33(2):336-9. PubMed ID: 18718659
[TBL] [Abstract][Full Text] [Related]
5. Hematological disorders and leukemia in children with Down syndrome.
Bruwier A; Chantrain CF
Eur J Pediatr; 2012 Sep; 171(9):1301-7. PubMed ID: 22113227
[TBL] [Abstract][Full Text] [Related]
6. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
7. Acute Leukemia in Down Syndrome Children in Hong Kong: Retrospective Review.
Lam GK; Leung AW; Ha SY; Luk CW; Li CH; Ling SC; Chiang AK; Li CK
J Pediatr Hematol Oncol; 2016 Mar; 38(2):102-6. PubMed ID: 26808367
[TBL] [Abstract][Full Text] [Related]
8. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
Frost BM; Gustafsson G; Larsson R; Nygren P; Lönnerholm G
Leukemia; 2000 May; 14(5):943-4. PubMed ID: 10803530
[No Abstract] [Full Text] [Related]
9. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
Palle J; Frost BM; Petersson C; Hasle H; Hellebostad M; Kanerva J; Schmiegelow K; Lönnerholm G;
Anticancer Drugs; 2009 Jan; 20(1):7-14. PubMed ID: 19342996
[TBL] [Abstract][Full Text] [Related]
10. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
11. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study.
Schmidt MP; Colita A; Ivanov AV; Coriu D; Miron IC
Medicine (Baltimore); 2021 Oct; 100(40):e27459. PubMed ID: 34622870
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
Buitenkamp TD; Mathôt RA; de Haas V; Pieters R; Zwaan CM
Haematologica; 2010 Jul; 95(7):1106-13. PubMed ID: 20418240
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychological late effects of treatment for acute leukemia in children with Down syndrome.
Roncadin C; Hitzler J; Downie A; Montour-Proulx I; Alyman C; Cairney E; Spiegler BJ
Pediatr Blood Cancer; 2015 May; 62(5):854-8. PubMed ID: 25545182
[TBL] [Abstract][Full Text] [Related]
15. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
16. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.
Hefti E; Blanco JG
Cardiovasc Toxicol; 2016 Jan; 16(1):5-13. PubMed ID: 25616318
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.
Goto H; Inukai T; Inoue H; Ogawa C; Fukushima T; Yabe M; Kikuchi A; Koike K; Fukushima K; Isoyama K; Saito T; Ohara A; Hanada R; Iwamoto J; Hotta N; Nagatoshi Y; Okamura J; Tsuchida M
Int J Hematol; 2011 Feb; 93(2):192-198. PubMed ID: 21286878
[TBL] [Abstract][Full Text] [Related]
19. Acute leukemias in children with Down syndrome.
Zwaan CM; Reinhardt D; Hitzler J; Vyas P
Hematol Oncol Clin North Am; 2010 Feb; 24(1):19-34. PubMed ID: 20113894
[TBL] [Abstract][Full Text] [Related]
20. Relationship of chromosome 21 and acute leukemia in children with Down syndrome.
Taub JW
J Pediatr Hematol Oncol; 2001; 23(3):175-8. PubMed ID: 11305722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
